

Completion of CMC, GLP-tox Testing, Clinical Trial Medication Production, and IND Approval for Orally Administerable CD39 Target Inhibitor Preclinical Candidate Substance

SCBIO Inc.


Disease Area	Neoplasm
Product Type	Small Molecule
Indication	Solid cancer, Pancreatic Cancer
Target	CD39
Mechanism of Action	Potent anti-tumor effect through boosting of anti-tumoral immunity in Tumor-associated microenvironment
Competitiveness	Down stream target of ATP/ADO signal axis, CD73 inhibitors such as Quemlistat (clinical phase 1b,,) Superiority of CD39 as drug target compared to CD73
Development Stage	Currently under CMC development, In this year (2024), it will be entered to GLP-tox for 2025 clinical trial
Route of Administration	Oral administration

Home phage: <http://www.sc-bio.co.kr/>

Key MOA:

ATP/ADO signal axis regulation Drug candidate, SCB001 (CD39 inhibitor)

Key Data



Anti-cancer immunity boosting mechanism of SCB001